Cullinan Management, Inc.

Market Summary

USD8.12-0.32

Market Closed

-3.79%

CGEM Stock Price

View Fullscreen

CGEM RSI Chart

CGEM Valuation

Market Cap

347.2M

Price/Earnings (Trailing)

-2.23

Price/Sales (Trailing)

4.16

EV/EBITDA

-1.78

Price/Free Cashflow

-2.44

CGEM Price/Sales (Trailing)

CGEM Profitability

EBT Margin

116.94%

Return on Equity

13.28%

Return on Assets

12.53%

Free Cashflow Yield

-40.96%

CGEM Fundamentals

CGEM Revenue

Revenue Y/Y

56.33%

CGEM Earnings

Earnings (TTM)

-155.9M

Earnings Y/Y

-57.97%

Earnings Q/Q

-21.63%

Price Action

Last 7 days

-5.7%

Last 30 days

-17.1%

Last 90 days

-23.4%

Trailing 12 Months

-31.2%

How does CGEM drawdown profile look like?

CGEM Financial Health

Current Ratio

15.25

CGEM Investor Care

Buy Backs (1Y)

6.52%

Diluted EPS (TTM)

-3.73

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	41.1M	63.2M	85.3M	107.4M
2021	0	0	0	18.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for CGEM

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 30, 2023	trigilio jeffrey	acquired	21,247	9.08	2,340	chief financial officer
Jun 28, 2023	ahmed nadim	sold	-8,652	11.4	-759	president and ceo
Jun 20, 2023	jones jeffrey alan	sold	-5,007	12.94	-387	chief medical officer
Jun 20, 2023	sumer jacquelyn l	sold	-3,765	12.94	-291	chief legal officer
Jun 20, 2023	michaelson jennifer	sold	-3,079	12.94	-238	chief development officer
Jun 20, 2023	trigilio jeffrey	sold	-5,163	12.94	-399	chief financial officer
Jun 12, 2023	michaelson jennifer	sold	-2,307	13.11	-176	chief development officer
Jun 12, 2023	trigilio jeffrey	sold	-4,182	13.11	-319	chief financial officer
Jun 07, 2023	michaelson jennifer	sold	-1,240	12.4	-100	chief development officer
Jun 07, 2023	michaelson jennifer	acquired	430	4.3	100	chief development officer

Which funds bought or sold CGEM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-44.33	-47,449	41,784	-%
Nov 21, 2023	COMERICA BANK	new	-	1,105	1,105	-%
Nov 17, 2023	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-901,096	-	-%
Nov 15, 2023	JANE STREET GROUP, LLC	reduced	-69.17	-429,424	150,357	-%
Nov 15, 2023	MORGAN STANLEY	reduced	-12.82	-933,021	2,564,920	-%
Nov 15, 2023	Rubric Capital Management LP	unchanged	-	-1,072,050	5,673,710	0.21%
Nov 15, 2023	Annandale Capital, LLC	added	20.00	1,000	109,000	0.03%
Nov 15, 2023	PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO	sold off	-100	-53,000	-	-%
Nov 15, 2023	MANUFACTURERS LIFE INSURANCE COMPANY, THE	unchanged	-	-18,283	96,763	-%
Nov 15, 2023	Baker Avenue Asset Management, LP	unchanged	-	-82.00	434	-%

Latest Funds Activity

Are funds buying CGEM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CGEM

No. of Funds

Schedule 13G FIlings of Cullinan Management, Inc.

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 07, 2023	blackrock inc.	4.8%	2,036,651	SC 13G/A
Feb 15, 2023	jovan-embiricos morana	3.4%	1,577,440	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	8.9%	4,058,854	SC 13G/A
Feb 13, 2023	chi advisors llc	7.25%	3,317,544	SC 13G/A
Feb 09, 2023	vanguard group inc	6.15%	2,812,965	SC 13G/A
Feb 03, 2023	blackrock inc.	5.5%	2,506,215	SC 13G
Feb 14, 2022	biotechnology value fund l p	6.4%	2,790,018	SC 13G/A
Feb 11, 2022	foresite capital fund v, l.p.	2.6%	1,143,006	SC 13G/A
Feb 11, 2022	chi advisors llc	5.67%	2,476,720	SC 13G
Feb 09, 2022	vanguard group inc	5.42%	2,366,808	SC 13G

Recent SEC filings of Cullinan Management, Inc.

View All Filings

Date Filed	Form Type	Document
Nov 08, 2023	8-K	Current Report
Nov 08, 2023	10-Q	Quarterly Report
Sep 07, 2023	SC 13G/A	Major Ownership Report

Peers (Alternatives to Cullinan Management, Inc.)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
HILS	31.4B	-	4.92%	426363.59%	-3.6K	218.4K	-	-102.45%
MRNA	30.7B	10.7B	11.84%	-53.56%	-8.86	2.88	-53.67%	-129.46%
ALNY	22.0B	1.7B	4.71%	-20.32%	-43.06	12.74	79.37%	56.87%
BMRN	17.7B	2.3B	23.54%	-7.88%	120.62	7.68	15.05%	75.21%
INCY	12.4B	3.6B	1.56%	-32.86%	29.22	3.44	8.35%	-51.49%
MID-CAP
APLS	7.5B	272.9M	38.55%	34.32%	-12.3	27.31	141.38%	4.43%
BBIO	5.6B	-	16.25%	246.63%	-9.66	48.33	54.84%	-12.96%
ACAD	3.5B	631.9M	-10.80%	43.56%	-23.57	5.55	23.54%	31.53%
AXSM	3.3B	223.4M	11.07%	-7.88%	-16.25	14.68	-	-26.24%
ARWR	2.6B	240.7M	-11.66%	-25.68%	-12.44	10.6	-1.03%	-16.59%
SMALL-CAP
CPRX	1.5B	348.4M	7.85%	-14.88%	24.07	4.29	81.69%	-7.29%
NVAX	662.5M	1.0B	-19.01%	-66.75%	-1.21	0.63	-43.15%	58.48%
INO	100.5M	6.4M	-2.56%	-78.77%	-0.61	15.6	-44.11%	50.48%
IBIO	42.3M	-	410.00%	-4.38%	-0.65	-	-	-29.23%
CRBP	26.3M	-	17.86%	4717.52%	-0.55	-	-	-13.74%

Cullinan Management, Inc. News

Latest updates

Financials for Cullinan Management, Inc.

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	-	-	-	173,566,000	86,783,000	-	-	-	18,943,000
Operating Expenses	19.1%	44,803,000	37,605,000	62,756,000	32,608,000	29,766,000	37,106,000	32,657,000	34,347,000	18,375,000	16,604,000	17,571,000
S&GA Expenses	7.5%	10,982,000	10,214,000	10,660,000	11,287,000	10,086,000	10,695,000	8,121,000	13,469,000	5,695,000	4,826,000	5,156,000
R&D Expenses	23.5%	33,821,000	27,391,000	52,096,000	21,321,000	19,680,000	26,411,000	24,536,000	20,878,000	12,680,000	11,778,000	12,415,000
EBITDA Margin	-	-	-	1.17	1.41	0.74	1.20	-5.16	-1.58	-0.40	-	-
Income Taxes	-	-	-	-	-1,858,000	-2,523,000	66,070,000	-19,568,000	-	-	-	-
Earnings Before Taxes	-21.6%	-39,183,000	-32,214,000	-58,141,000	-28,946,000	-27,413,000	240,135,000	-32,460,000	-34,206,000	-18,259,000	-16,439,000	1,419,000
EBT Margin	-	-	-	1.17	1.41	0.74	1.20	-5.16	-1.59	-0.40	-	-
Net Income	-21.6%	-39,183,000	-32,214,000	-58,141,000	-26,385,000	-24,804,000	174,898,000	-12,892,000	-32,857,000	-17,350,000	-16,439,000	1,419,000
Net Income Margin	-	-	-	0.60	1.04	0.52	0.33	-4.10	-3.46	-0.81	-	-0.33
Free Cashflow	-	-	-	-51,156,000	-25,865,000	-54,436,666	-	-21,908,000	-15,171,000	-10,551,000	-16,196,000	-1,515,000

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-5.2%	495	522	515	561	617	667	437	437	453	464	480	215
Current Assets	-4.3%	477	498	399	474	582	623	322	297	329	344	447	212
Cash Equivalents	-54.3%	65.00	142	122	156	243	354	76.00	60.00	88.00	124	294	168
Net PPE	-7.9%	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	15.5%	26.00	22.00	29.00	26.00	31.00	63.00	18.00	12.00	8.00	6.00	10.00	14.00
Current Liabilities	19.2%	23.00	20.00	26.00	22.00	27.00	62.00	17.00	12.00	8.00	6.00	10.00	14.00
Shareholder's Equity	-6.2%	469	500	486	535	586	605	419	425	445	459	470	200
Retained Earnings	-28.4%	-177	-137	-105	-47.69	-20.91	4.00	-171	-158	-126	-109	-93.41	-93.34
Additional Paid-In Capital	1.2%	647	639	593	585	611	604	593	585	570	565	560	292
Shares Outstanding	0.1%	43.00	43.00	39.00	46.00	46.00	45.00	44.00	44.00	43.00	43.00	42.00	30.00
Minority Interest	-	-	-	-	-	-	0.00	1.00	0.00	2.00	3.00	3.00	1.00

Cashflow (Last 12 Months)
(In Millions)

Cashflow (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-10.1%	-34,141,000	-31,006,000	-50,997,000	-24,983,000	-54,353,000	-25,420,000	-21,908,000	-15,171,000	-10,551,000	-16,196,000	-1,515,000	-9,436,000	-9,071,000	-6,250,000	-5,015,000
Share Based Compensation	-2.3%	7,740,000	7,920,000	7,259,000	7,513,000	5,271,000	8,608,000	6,565,000	12,145,000	4,557,000	4,165,000	3,508,000	-	-	-	-
Cashflow From Investing	-454.7%	-42,958,000	12,110,000	15,184,000	-28,610,000	-57,978,000	300,852,000	34,711,000	-15,862,000	-25,593,000	-154,594,000	-137,726,000	11,440,000	-1,941,000	11,971,000	-26,890,000
Cashflow From Financing	-99.7%	112,000	38,602,000	1,789,000	-32,912,000	1,425,000	2,013,000	3,541,000	2,702,000	579,000	923,000	264,580,000	124,897,000	1,206,000	-	14,037,000
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	6,359,000	-	-	213,000

CGEM Income Statement

2023-09-30

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Income (loss) from operations	$ (45,243)	$ (29,766)	$ (145,604)	$ 177,256
Operating expenses:
Research and development	33,821	19,680	113,308	70,627
General and administrative	10,982	10,086	31,856	28,902
Total operating expenses	44,803	29,766	145,164	99,529
Gain on sale of Cullinan Pearl	0	0	0	276,785
Impairment of long-lived assets	(440)	0	(440)	0
Other income (expense):
Interest income	5,880	2,353	15,710	3,247
Other income (expense), net	180	0	356	(241)
Net income (loss) before income taxes	(39,183)	(27,413)	(129,538)	180,262
Income tax expense (benefit)	0	(2,523)	0	43,979
Net income (loss)	(39,183)	(24,890)	(129,538)	136,283
Net loss attributable to noncontrolling interests	0	(86)	(179)	(1,713)
Net income (loss) attributable to common stockholders of Cullinan	(39,183)	(24,804)	(129,359)	137,996
Comprehensive income (loss):
Net income (loss)	(39,183)	(24,890)	(129,538)	136,283
Unrealized gain on investments	574	(296)	1,550	(3,091)
Comprehensive income (loss)	(38,609)	(25,186)	(127,988)	133,192
Comprehensive loss attributable to noncontrolling interests	0	(86)	(179)	(1,713)
Comprehensive income (loss) attributable to Cullinan	$ (38,609)	$ (25,100)	$ (127,809)	$ 134,905
Net income (loss) per share attributable to common stockholders of Cullinan:
Basic	$ (0.91)	$ (0.54)	$ (3.15)	$ 3.07
Diluted	$ (0.91)	$ (0.54)	$ (3.15)	$ 2.96
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders of Cullinan
Weighted-average common stock outstanding - basic	42,734	45,611	41,130	44,966
Diluted	42,734	45,611	41,130	46,580

CGEM Balance Sheet

2023-09-30

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 64,847	$ 156,152
Short-term investments	401,583	311,140
Prepaid expenses and other current assets	10,282	7,180
Total current assets	476,712	474,472
Property and equipment, net	1,066	1,174
Operating lease right-of-use assets	2,925	4,130
Other assets	459	459
Long-term investments	13,545	80,882
Total assets	494,707	561,117
Current liabilities:
Accounts payable	951	2,660
Accrued expenses and other current liabilities	20,946	14,135
Income tax payable	0	4,282
Operating lease liabilities, current	1,547	1,421
Total current liabilities	23,444	22,498
Long-term liabilities:
Operating lease liabilities, net of current portion	2,446	3,590
Total liabilities	25,890	26,088
Commitments and contingencies (Note 11)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 647,500 and no shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2023 and December 31, 2022; 42,760,644 and 45,796,449 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	4	5
Additional paid-in capital	646,918	585,320
Accumulated other comprehensive loss	(1,051)	(2,601)
Accumulated deficit	(177,054)	(47,695)
Total Cullinan stockholders' equity	468,817	535,029
Noncontrolling interests	0	0
Total stockholders' equity	468,817	535,029
Total liabilities and stockholders' equity	$ 494,707	$ 561,117

About Cullinan Management, Inc.

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nadim Ahmed
WEBSITE	www.cullinanoncology.com
EMPLOYEES	62

Cullinan Management, Inc. Frequently Asked Questions

What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cullinan Management, Inc. (CGEM)?

As of Wed Dec 06 2023, market cap of Cullinan Management, Inc. is 347.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart. The fair value of Cullinan Management, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cullinan Management, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cullinan Management, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGEM is over valued or under valued. Whether Cullinan Management, Inc. is cheap or expensive depends on the assumptions which impact Cullinan Management, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGEM.

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, CGEM's PE ratio (Price to Earnings) is -2.23 and Price to Sales (PS) ratio is 4.16. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

CGEM Stock Price

CGEM RSI Chart

CGEM Valuation

CGEM Price/Sales (Trailing)

CGEM Profitability

CGEM Fundamentals

CGEM Revenue

CGEM Earnings

Price Action

How does CGEM drawdown profile look like?

CGEM Financial Health

CGEM Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for CGEM

Which funds bought or sold CGEM recently?

Latest Funds Activity

Schedule 13G FIlings of Cullinan Management, Inc.

Recent SEC filings of Cullinan Management, Inc.

Peers (Alternatives to Cullinan Management, Inc.)

Cullinan Management, Inc. News

Financials for Cullinan Management, Inc.

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)(In Millions)

CGEM Income Statement

CGEM Balance Sheet

About Cullinan Management, Inc.

Cullinan Management, Inc. Frequently Asked Questions

What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

What is the market capital of Cullinan Management, Inc. (CGEM)?

What is the fair value of CGEM stock?

Is Cullinan Management, Inc. a good stock to buy?

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

Balance Sheet
(In Millions)

Cashflow (Last 12 Months)
(In Millions)